Navigation Links
EnteroScreen 4™

ProductsEnteroScreen 4™
Company Hardy Diagnostics
Item EnteroScreen 4™
Features 
  • Time Savings - Inoculate only one tube per specimen instead of the classical 3 to 4 tubes. Quickly eliminate your negatives.
  • Accuracy - Found to be 100% accurate for Salmonella and Shigella when challenged against 218 clinical specimens and over 24 serotypes.
  • Convenience - You can pick colonies directly from the modified LIA slant for antisera confirmation.
  • Economical - Priced far less then other screening methods. Compare the cost savings to an API strip, Vitek, or Microscan card.
  • Ease of Use - Simply use your inoculation needle and penetrate the four layers in the tube, then remove and incubate. The urea agar can come up positive in as early as 6 hours.
Description The simple, easy and accurate one tube system for screening of stool specimens for Salmonella and Shigella species. EnteroScreen 4™ is specifically designed to rule out normal enteric flora and to aid in the detection and the differentiation of Salmonella and Shigella species. Three media, Modified Lysine Iron Agar, Lysine Iron Agar (LIA), and Urea Agar, are used to screen non-lactose fermentors isolated from stool specimens. This battery of tests is helpful in differentiating Salmonella and Shigella from other members of the Enterobacteriaceae family. Hardy Diagnostics EnteroScreen 4™ contains a unique media combination, which has been demonstrated to be less redundant and less labor intensive; yet equivalent in performance to the traditional three tube set.
Info Hardy Diagnostics
Customer Service: (800) 266-2222
Web site: http://www.hardydiagnostics.com

Related medicine products :

1. Quad 4™ Intramedullary Nail System
2. Opti4™ Curved Spatula Tip Electrode
3. Opti4™ Flat L Hook Tip Electrode
4. Opti4™ Straight Spatula Tip Electrode
5. Opti4™ Cylindrical Tip Electrode
6. Opti4™ Wire J Hook Tip Electrode
7. Opti4™ Pencil Grip Laparoscopic Handset
Breaking Medicine Technology:Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5Soothing Imagery May Help Rid Some Kids of Stomach Pain 59350 1Soothing Imagery May Help Rid Some Kids of Stomach Pain 59350 2ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales 14443 1ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales 14443 2ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales 14443 3Solta Medical Inc Appoints Jeffrey Nardoci Vice President of Global Marketing 59347 1Solta Medical Inc Appoints Jeffrey Nardoci Vice President of Global Marketing 59347 2